{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-062865","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-05-15T23:55:16+00:00","discovered_at":"2026-05-18T10:05:00.355486+00:00","generated_at":"2026-05-18T10:06:42.229448+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Outlook Therapeutics Q2 FY2026 net loss narrows to $4.5M; FDA decision on ONS-5010 expected May 2026","bullets":["Net loss of $4.5M ($0.05/sh) vs $46.4M ($1.50/sh) YoY; adjusted net loss $14.1M ($0.16/sh).","LYTENAVA unit sales in Europe down ~10% QoQ; cost reduction steps initiated to improve margins.","Cash $7.7M as of Mar 31; raised ~$4M in March offering and $4.2M net in April registered direct offering.","FDA formal dispute resolution meeting completed in April; written decision expected within May 2026.","Entered Swiss distribution agreement with Mediconsult AG; targeting 2027 launch pending marketing authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-062865","json":"https://secwatch.observer/filing/0001104659-26-062865.json","markdown":"https://secwatch.observer/filing/0001104659-26-062865.md","text":"https://secwatch.observer/filing/0001104659-26-062865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/0001104659-26-062865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/tm2614868d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T10:06:42.229448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ad1f8c803e15712fb0874aefaada551b528c481","claim":"Outlook Therapeutics, Inc. reported second fiscal quarter ended March 31, 2026 results: net income net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share.","evidence_excerpt":"Outlook Therapeutics reported net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/0001104659-26-062865-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second fiscal quarter ended March 31, 2026"},{"label":"Net income","value":"net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}